L-Tryptophan Depletion Using a New Bioreactor: A Possible New Cancer Therapy DOI Open Access

Journal of Clinical & Experimental Immunology, Год журнала: 2023, Номер 8(3)

Опубликована: Июль 20, 2023

Not all cancer therapeutic strategies known to date are adequate for patients. Most of them followed by a high rate severe side effects and complications. L-Tryptophan metabolism plays key role in organism development, as well the occurrence development tumors. By degrading certain amino acids, tumor growth can be limited while maintaining body´s normal nutritional requirements. The L-tryptophan depletion bioreactor is described possible new method therapy. an essential acid that has been recognized important nutrient its removal lead destruction cells. Tumor cells or human cannot synthesize therefore resistance unlikely develop. also constituent different biomolecules such Sero-tonin, Melatonin, needed other synthesis processes cell growth. enzymes with three iso-enzymes called tryptophan chain oxydase (TSO) I, II, III have molecular weights effectiveness. All TSO heme catalyze essentially similar reactions involving substrate. most effective type III. A column, which contained TSO, immobilized on silica beats bioreactor, was integrated plasmapheresis unit tested it animals. In sheep rabbits, plasma shown at 95% 100% rates respectively single pass through bioreactor. 20 lines, there were efficacies. Brest medulloblastoma showed greatest efficacy degrading. gene technology production from Pseudomonas associated formation endotoxins. These endotoxins must eliminated. Bioreactors developed treat diseases successfully low effects. combination available thera-pies possible.

Язык: Английский

Advances in dendritic cell vaccination therapy of cancer DOI Open Access
Sajad Najafi, Keywan Mortezaee

Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 164, С. 114954 - 114954

Опубликована: Май 29, 2023

Traditionally, vaccines have helped eradication of several infectious diseases and also saved millions lives in the human history. Those prophylactic acted through inducing immune responses against a live attenuated, killed organism or antigenic subunits to protect recipient real infection caused by pathogenic microorganism. Nevertheless, development anticancer as valuable targets health has faced challenges requires further optimizations. Dendritic cells (DCs) are most potent antigen presenting (APCs) that play essential roles tumor immunotherapies induction CD8+ T cell immunity. Accordingly, various strategies been tested employ DCs therapeutic for exploiting their activity cells. Application whole purified/recombinant peptides common approaches pulsing DCs, which then injected back into patients. Although some hopeful results reported number DC animal clinical trials cancer patients, such still inefficient require optimization. Failure vaccination is postulated due immunosuppressive microenvironment (TME), overexpression checkpoint proteins, suboptimal avidity tumor-associated (TAA)-specific lymphocytes, lack appropriate adjuvants. In this review, we an overview current experiments evaluated efficacy well focusing on improve potential including combination therapy with inhibitors (ICIs).

Язык: Английский

Процитировано

53
The role of microRNAs in the pathophysiology of human central nervous system: A focus on neurodegenerative diseases DOI
Delsuz Rezaee,

Fatemeh Saadatpour,

Nayyereh Akbari

и другие.

Ageing Research Reviews, Год журнала: 2023, Номер 92, С. 102090 - 102090

Опубликована: Окт. 11, 2023

Язык: Английский

Процитировано

44
HDAC-targeting epigenetic modulators for cancer immunotherapy DOI
Binbin Cheng, Wei Pan, Yao Xiao

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 265, С. 116129 - 116129

Опубликована: Янв. 5, 2024

Язык: Английский

Процитировано

32
Extracellular vesicle–based drug delivery in cancer immunotherapy DOI Open Access
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee

и другие.

Drug Delivery and Translational Research, Год журнала: 2023, Номер 13(11), С. 2790 - 2806

Опубликована: Июнь 1, 2023

Язык: Английский

Процитировано

38
Mass‐produced gram‐negative bacterial outer membrane vesicles activate cancer antigen‐specific stem‐like CD8+ T cells which enables an effective combination immunotherapy with anti‐PD‐1 DOI Creative Commons

Solchan Won,

Changjin Lee,

Seoyoon Bae

и другие.

Journal of Extracellular Vesicles, Год журнала: 2023, Номер 12(8)

Опубликована: Авг. 1, 2023

Despite the capability of extracellular vesicles (EVs) derived from Gram-negative and Gram-positive bacteria to induce potent anti-tumour responses, large-scale production bacterial EVs remains as a hurdle for their development novel cancer immunotherapeutic agents. Here, we developed manufacturing processes mass Escherichia coli EVs, namely, outer membrane (OMVs). By combining metal precipitation size-exclusion chromatography, isolated 357 mg in total protein amount E. OMVs, which was equivalent 3.93 × 1015 particles (1.10 1010 particles/μg amounts OMVs) 160 L conditioned medium. We show that these mass-produced OMVs led complete remission two mouse syngeneic tumour models. Further analysis microenvironment neoantigen-expressing models revealed OMV treatment causes increased infiltration activation CD8+ T cells, especially those antigen-specific cells with high expression TCF-1 PD-1. Furthermore, showed synergistic activity anti-PD-1 antibody immunotherapy, inducing substantial growth inhibition activated stem-like into microenvironment. These data highlight activities candidate developing next-generation

Язык: Английский

Процитировано

33
The role of microRNA-185 in the pathogenesis of human diseases: A focus on cancer DOI Open Access
Safoora Pordel,

Motahare Khorrami,

Fatemeh Saadatpour

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 249, С. 154729 - 154729

Опубликована: Авг. 16, 2023

Язык: Английский

Процитировано

30
The role of the gut microbiota in tumor, immunity, and immunotherapy DOI Creative Commons
Yuyan Xie, Fang Liu

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июнь 5, 2024

In recent years, with the deepening understanding of gut microbiota, it has been recognized to play a significant role in development and progression diseases. Particularly gastrointestinal tumors, microbiota influences tumor growth by dysbiosis, release bacterial toxins, modulation host signaling pathways immune status. Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment efficacy enhancing cell responses. Current clinical preclinical studies demonstrated that its metabolites can enhance effectiveness immunotherapy. Furthermore, certain serve as biomarkers for predicting immunotherapy Interventions targeting diseases, especially colorectal (CRC), include fecal transplantation, probiotics, prebiotics, engineered bacteria, dietary interventions. These approaches not only improve ICIs but also hold promise outcomes. this review, we primarily discuss immunity,

Язык: Английский

Процитировано

14
microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance DOI Creative Commons
Mehdi Fattahi, Delsuz Rezaee,

Fatemeh Fakhari

и другие.

Cell Death Discovery, Год журнала: 2023, Номер 9(1)

Опубликована: Ноя. 24, 2023

Abstract MicroRNAs (miRNAs) are a class of non-coding RNAs (ncRNAs) with short length 19–22 nucleotides. miRNAs posttranscriptional regulators gene expression involved in various biological processes like cell growth, apoptosis, and angiogenesis. miR-184 is well-studied miRNA, for which most studies report its downregulation cancer cells tissues experiments support role as tumor suppressor inhibiting malignant behaviors vitro vivo. To exert functions, affects some signaling pathways tumorigenesis Wnt β-catenin, AKT/mTORC1 pathway, oncogenic factors (e.g., c-Myc) or apoptotic proteins, such Bcl-2. Interestingly, clinical investigations have shown good performance prognostic/diagnostic biomarker cancers. Additionally, exogenous xenograft animal suggest it therapeutic anticancer target. In this review, we outline the that evaluated roles well significance.

Язык: Английский

Процитировано

22
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies DOI
Sajad Najafi, Keywan Mortezaee

Life Sciences, Год журнала: 2023, Номер 338, С. 122387 - 122387

Опубликована: Дек. 26, 2023

Язык: Английский

Процитировано

16
Alternative immune checkpoints in immunoregulatory profile of cancer stem cells DOI Creative Commons
Keywan Mortezaee, Jamal Majidpoor

Heliyon, Год журнала: 2023, Номер 9(12), С. e23171 - e23171

Опубликована: Дек. 1, 2023

Tumor-mediated bypass of immune checkpoint inhibitor (ICI) therapy with anti-programmed death-1 (PD-1), death-ligand 1 (PD-L1, also called B7-H1 or CD274) anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is a challenge current years in the area cancer immunotherapy. Alternative checkpoints (AICs) are molecules beyond common PD-1, PD-L1 CTLA-4, and upregulated patients who show low/no ICI responses. These members B7 family including B7-H2 (ICOS-L), B7-H3 (CD276), B7-H4 (B7x), V-domain immunoglobulin suppressor cell activation (VISTA), B7-H6, HHLA2 (B7-H5/B7-H7) catabolic enzymes like indoleamine 2,3-dioxygenase (IDO1), others that contributed to regulation tumor microenvironment (TIME). There strong evidence supporting implication AICs stemness expanding population stem cells (CSCs). CSCs display immunoregulatory capacity represent multiple either on their surface inside. Besides, they active promoters resistance ICIs. The aim this review investigate interrelations between differentiation profile cancer. key message paper targeted can be selected based impact along effect cells. Studies published so far mainly focused as target for anti-checkpoints. Ex vivo engineering extracellular vesicles (EVs) equipped CSC-targeted anti-checkpoint antibodies without doubt therapeutic under consideration future research.

Язык: Английский

Процитировано

11